Physician profile
Jayme Boros
NPI 1265940977
$914.45
in general payments reported to CMS, 2019-2025
15 companies · $329 in 2025
The $329 reported for 2025 was more than what 87% of Pediatrics (Nurse Practitioner) providers received nationally (typical 2025 total: $93.49).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $58.07 · 2023: $269 · 2024: $259 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $159.09 | 2023-2025 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $128.60 | 2023-2025 | |
| Seqirus USA INC | $113.28 | 2022-2025 | Flucelvax Quadrivalent, Flucelvax |
| Phadia US INC. | $84.45 | 2022-2025 | Immunocap |
| Sanofi Pasteur INC. | $53.57 | 2023-2024 | |
| Verrica Pharmaceuticals INC. | $51.17 | 2023-2024 | Ycanth |
| Collegium Pharmaceutical, INC. | $50.16 | 2025 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $46.63 | 2022-2025 | Elaprase |
| Supernus Pharmaceuticals, INC. | $42.14 | 2024-2025 | Qelbree |
| Sobi, INC | $41.04 | 2023 | |
| Ars Pharmaceuticals Operations, INC. | $39.82 | 2025 | Neffy |
| Cranial Technologies, INC | $29.25 | 2025 | Doc Band |
| Sanofi-Aventis U.S. LLC | $26.85 | 2025 | |
| Ironwood Pharmaceuticals, INC | $26.59 | 2024 | |
| Glaxosmithkline, LLC. | $21.81 | 2025 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayme Boros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.